BR112022022220A2 - Composto, composição farmacêutica, uso do composto, e método para tratar, regular e/ou prevenir uma doença relacionada a uma proteína mutante de egfr - Google Patents
Composto, composição farmacêutica, uso do composto, e método para tratar, regular e/ou prevenir uma doença relacionada a uma proteína mutante de egfrInfo
- Publication number
- BR112022022220A2 BR112022022220A2 BR112022022220A BR112022022220A BR112022022220A2 BR 112022022220 A2 BR112022022220 A2 BR 112022022220A2 BR 112022022220 A BR112022022220 A BR 112022022220A BR 112022022220 A BR112022022220 A BR 112022022220A BR 112022022220 A2 BR112022022220 A2 BR 112022022220A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- regulating
- preventing
- treatment
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010486394 | 2020-06-01 | ||
| CN202010947590 | 2020-09-10 | ||
| CN202110587528 | 2021-05-27 | ||
| PCT/CN2021/097583 WO2021244505A1 (zh) | 2020-06-01 | 2021-06-01 | 新型吡嗪化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022220A2 true BR112022022220A2 (pt) | 2022-12-13 |
Family
ID=78830119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022220A BR112022022220A2 (pt) | 2020-06-01 | 2021-06-01 | Composto, composição farmacêutica, uso do composto, e método para tratar, regular e/ou prevenir uma doença relacionada a uma proteína mutante de egfr |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12600714B2 (enExample) |
| EP (1) | EP4159731A4 (enExample) |
| JP (1) | JP7777544B2 (enExample) |
| KR (1) | KR20230019444A (enExample) |
| CN (1) | CN115698000B (enExample) |
| AU (1) | AU2021284676A1 (enExample) |
| BR (1) | BR112022022220A2 (enExample) |
| CA (1) | CA3179395A1 (enExample) |
| MX (1) | MX2022013397A (enExample) |
| TW (1) | TWI845843B (enExample) |
| WO (1) | WO2021244505A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4373817B1 (en) * | 2021-07-20 | 2025-05-21 | Astrazeneca AB | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| WO2003045924A1 (en) * | 2001-11-21 | 2003-06-05 | Pharmacia & Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
| JP5364159B2 (ja) * | 2009-05-08 | 2013-12-11 | アステラス製薬株式会社 | ジアミノへテロ環カルボキサミド化合物 |
| WO2013108754A1 (ja) | 2012-01-17 | 2013-07-25 | アステラス製薬株式会社 | ピラジンカルボキサミド化合物 |
| CA2975072A1 (en) * | 2015-01-28 | 2016-08-04 | Astellas Pharma Inc. | Method for producing pyrazinecarboxamide compound and synthetic intermediate thereof |
| MA42623A (fr) | 2015-06-02 | 2018-06-20 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| WO2018103663A1 (zh) * | 2016-12-09 | 2018-06-14 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途 |
| EP3656769B1 (en) | 2017-07-19 | 2023-01-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor |
-
2021
- 2021-06-01 BR BR112022022220A patent/BR112022022220A2/pt unknown
- 2021-06-01 TW TW110119810A patent/TWI845843B/zh active
- 2021-06-01 JP JP2022574270A patent/JP7777544B2/ja active Active
- 2021-06-01 WO PCT/CN2021/097583 patent/WO2021244505A1/zh not_active Ceased
- 2021-06-01 MX MX2022013397A patent/MX2022013397A/es unknown
- 2021-06-01 EP EP21817710.3A patent/EP4159731A4/en active Pending
- 2021-06-01 US US17/917,435 patent/US12600714B2/en active Active
- 2021-06-01 CN CN202180039487.2A patent/CN115698000B/zh active Active
- 2021-06-01 CA CA3179395A patent/CA3179395A1/en active Pending
- 2021-06-01 KR KR1020227044988A patent/KR20230019444A/ko active Pending
- 2021-06-01 AU AU2021284676A patent/AU2021284676A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115698000B (zh) | 2026-02-24 |
| CN115698000A (zh) | 2023-02-03 |
| JP2023528859A (ja) | 2023-07-06 |
| TW202146406A (zh) | 2021-12-16 |
| EP4159731A1 (en) | 2023-04-05 |
| AU2021284676A1 (en) | 2023-02-02 |
| TWI845843B (zh) | 2024-06-21 |
| KR20230019444A (ko) | 2023-02-08 |
| JP7777544B2 (ja) | 2025-11-28 |
| WO2021244505A1 (zh) | 2021-12-09 |
| US20230167099A1 (en) | 2023-06-01 |
| CA3179395A1 (en) | 2021-12-09 |
| EP4159731A4 (en) | 2024-06-26 |
| MX2022013397A (es) | 2022-12-13 |
| US12600714B2 (en) | 2026-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023001195A2 (pt) | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto | |
| BR112022018646A2 (pt) | Composto agonista do receptor glp-1, composição farmacêutica compreendendo o mesmo, métodos para preparar o composto e uso do dito composto para prevenir ou tratar uma doença metabólica ou uma doença neurodegenerativa | |
| KR101605151B1 (ko) | 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드 | |
| BR112017017078A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença. | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| MX2020002429A (es) | Compuestos para reducir la viscosidad de las formulaciones biologicas. | |
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| PY1978496A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| MX2020008498A (es) | Derivados de sobetirome. | |
| JP2016516773A5 (enExample) | ||
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| MX2020004667A (es) | Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas. | |
| MX2025009098A (es) | Sal y forma cristalina de un compuesto cicloalquenico y metodo de preparacion de estos y uso de estos | |
| BR112023025251A2 (pt) | Composto ou sal, éster, solvato, pró-fármaco, derivado marcado com isótopo ou isômero farmaceuticamente aceitável deste, composição, composição farmacêutica e método para tratamento de uma doença ou distúrbio inibindo a transdução de sinal mediada por tyk2 | |
| BR112022009533A2 (pt) | Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica | |
| TWI557128B (zh) | 組成物在製備用於預防或治療非小細胞肺癌之藥物之用途 | |
| BR112021022966A2 (pt) | Método para reduzir o tamanho do tumor | |
| BR112022008074A2 (pt) | Composto de ácido oxocarboxílico heterocíclico de cinco membros e uso médico do mesmo | |
| US20200281918A1 (en) | Calcium release-activated calcium channel modulators for treating hematological and solid cancers | |
| BR112022007974A2 (pt) | Inibidores de ssao e uso dos mesmos | |
| CO2024002712A2 (es) | Azálidos inmunomoduladores | |
| BR112021024139A2 (pt) | Composto de fórmula geral (i) ou um sal farmaceuticamente aceitável do mesmo | |
| US20200237743A1 (en) | Crac channel modulators for treating esophageal cancer | |
| MX2022013397A (es) | Nuevo compuesto de pirazina. | |
| MX2021009188A (es) | Uso de composición que contiene inhibidor de quinasa dependiente de ciclina 4/6 en combinación con anastrozol en la preparación de medicamentos para el tratamiento de enfermedades tumorales. |